Inovio shares surge 300% after FDA approves Voceryq for rare disease
Inovio shares jumped about 300% after the FDA approved Voceryq for a rare disease, as reported by Seeking Alpha on October 30, 2026.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Inovio shares rose about 300% after the US Food and Drug Administration approved Voceryq, a treatment for a rare disease.
Seeking Alpha reported the move. The publisher notes that its content is for information only and does not constitute personal investment advice.
why it matters
Moves of this size are typical for small biotech companies, where a single regulatory decision can quickly reset the valuation of the business. The text does not detail the drug's commercial outlook, so its effect on the company's financials is hard to gauge for now.
tags
instruments
sources
- Inovio surges 300% following FDA approval of Voceryq for rare disease — Seeking Alpha, 30 October 2026 at 21:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗